Joel Hecht, MD
Hematology & Oncology · Los Angeles, CANPI 1790703742
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,743 of the $54,212 with a category attached, or 80.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2019 at $16,070 and has fallen 51.1% since, to $7,861 in 2025.
Across 63 payments — averaging $860.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Merck$10K
- E.r. Squibb & Sons, L.L.C.$6K
- Gilead$4K
- Genmab U.S., Inc.$3K
- Deciphera Pharmaceuticals Inc.$3K
- plus $18K from 19 others
Across 226 payments — averaging $17,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.1M
- GSK$621K
- Merck$553K
- Janssen Research & Development, LLC$403K
- Exelixis Inc.$390K
- Pfizer$334K
- plus $545K from 6 others
What the payments were for
- Consulting fees$43,74381%
- Speaking & faculty fees$2,8505%
- Travel & lodging$5,50510%
- Food & beverage$2,0434%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $10,384 |
| Merck | 14 | $9,778 |
| E.r. Squibb & Sons, L.L.C. | 13 | $6,308 |
| Gilead | 2 | $3,644 |
| Genmab U.S., Inc. | 1 | $3,200 |
| Deciphera Pharmaceuticals Inc. | 1 | $2,580 |
| Boehringer Ingelheim | 1 | $2,538 |
| Ipsen Biopharmaceuticals, Inc | 3 | $2,318 |
| Taiho Oncology, Inc. | 3 | $2,172 |
| Exelixis Inc. | 1 | $1,980 |
| Eli Lilly | 5 | $1,533 |
| Novartis | 1 | $1,519 |
| Aurobindo Pharma USA, Inc. | 1 | $1,500 |
| Amgen | 2 | $978 |
| Urogen Pharma, Inc. | 1 | $897 |
| Ipsen Pharma SAS | 1 | $870 |
| Ipsen Innovation | 1 | $870 |
| Corcept Therapeutics | 1 | $600 |
| Pfizer | 2 | $134 |
| Regeneron | 1 | $117 |
| Seagen Inc. | 1 | $105 |
| Mirati Therapeutics, Inc. | 1 | $79 |
| GSK | 1 | $67 |
| Janssen Research & Development, LLC | 1 | $38 |
| Array Biopharma Inc | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,212 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.